Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/32/43/8d/32438d12-f214-2b84-a090-4cb5c1fd55ff/mza_1588204697638323759.jpg/600x600bb.jpg

Project Oncology®

ReachMD

180 episodes

4 days ago

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

Science

Medicine

RSS

All content for Project Oncology® is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Medicine

Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma

Project Oncology®

1 month ago

Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma

Host: Ryan Quigley

In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.